Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study

What Was Tested

This randomized controlled trial paper looks at Retatrutide.

WHAT IS THE CONTEXT AND PURPOSE OF THIS RESEARCH STUDY?: Retatrutide is a new treatment currently being developed for people with obesity and people with type 2 diabetes.

WHAT IS THE ORIGINALITY AND RELEVANCE OF THIS STUDY?: This is the first study to assess changes in appetite and eating behaviours of adults with type 2 diabetes who received retatrutide.

Why It Was Studied

The researchers examined changes in feelings of hunger, satisfaction and fullness, the desire to eat certain types of foods (e.g., sweet, salty or fatty foods), the tendency to overeat (e.g., when stressed), and conscious efforts to limit food intake.

The researchers also examined the potential link between changes in appetite or eating behaviours and changes in weight during retatrutide treatment.

Who Took Part

According to the abstract, 12 adults were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

This study compared the changes in appetite and eating behaviours of adults with T2D who were treated with retatrutide, dulaglutide (an alternative treatment), or placebo (i.e., no treatment).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Retatrutide group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received Retatrutide.

A placebo (an inactive look-alike) gave the Retatrutide group a baseline to be compared against.

Changes from baseline with retatrutide were compared to those with placebo and dulaglutide.

Post-hoc correlations between changes in body weight and Appetite VAS/EI scores were also examined.

What Was Measured

WHAT WAS DONE?: Adults with type 2 diabetes who participated in this trial completed two questionnaires that measured their eating habits at several time points during the 36-week period in which they received treatment.

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Appetite, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Hypoglycemic Agents and Feeding Behavior.

The authors tagged it with the keywords Retatrutide, dietary restraint, disinhibition, eating attitudes, eating behaviours and phase 2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Retatrutide in 12 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Retatrutide compound page, all human trials.